Fda

Use of aromatase inhibitor forms basis of warning letter

Use of aromatase inhibitor forms basis of warning letter

By Hank Schultz

A recently posted warning letter cites a New York company for the presence of an aromatase inhibitor in one of its dietary supplements. This class of chemicals is popular with strength trainers for its purported ability to suppress estrogen levels.

'The substance is well known, under surveillance and forbidden,' a spokesperson for the Austrian food agency says. ©iStock.com/Pogonici

Summer of DMAA: Spate of imports blocked in EU

By Annie Harrison-Dunn

There have been several cases of the dangerous stimulant 1,3-dimethylamylamine (DMAA) being blocked at the EU borders over the last few months. But what is being done to stem the flow of the outlawed ingredient?

Will the market or FDA deliver the final blow for DMAA?

Will the market or FDA deliver the final blow for DMAA?

By Stephen Daniells

There is a moment at the end of the legendary computer game, Mortal Kombat, where you have just beaten seven shades of something out of your opponent and all that is left is one final blow. ‘Finish him!’ says the game, and you ready your thumbs for the coup...

Credit where credit is due: FDA activity is a good thing

FDA's enforcement deserves loud applause

By Stephen Daniells

A flurry of seizures, criminal charges, and warning letters shows that FDA is increasing it enforcement of dietary supplement regulations. Good for FDA and good for industry!

A transatlantic view of regulations and health claims

A transatlantic view of regulations and health claims

By Stephen Daniells

Should the FDA work to be more like EFSA? Speaking at the NutraIngredients Health Claims 2010 conference Andrew Shao said the two organisations are already very similar in the way they review scientific claims.

Spotlight

Follow us

Featured Events

View more

Products

View more

Webinars

Featured Suppliers

All suppliers